TITLE

IVAX Gets Final Approval for European Marketing of Paxene

PUB. DATE
September 1999
SOURCE
Worldwide Biotech;Sep99, Vol. 11 Issue 9, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the European Commission's signing a decision to grant a Marketing Authorization for IVAX Corp.'s propriety anti-cancer drug, Paxene (paclitaxel). Remarks from Phillip Frost, IVAX Corp. chairman; Details on IVAX 's Abbreviated New Drug Application pending in the United States for a generic form of Taxol; Preliminary results of IVAX's Paxoral.
ACCESSION #
2219617

 

Related Articles

  • Play it again, Sam. Reingold, Jennifer // Financial World;3/11/96, Vol. 165 Issue 4, p24 

    Focuses on Phillip Frost's management strategies for generic drug maker Ivax's finance as its chief executive officer and founder. Confidence of shareholders in Frost; Growth of Ivax since its inception; Frost's track record in finance; Frost's use of a strong stock price to build a...

  • IVAX Seeking to Acquire Elf Atochem North America.  // Textile Chemist & Colorist;Jun93, Vol. 25 Issue 6, p7 

    The article reports that IVAX Corp. is seeking to acquire the textile chemical and janitorial businesses of Elf Atochem North America Inc. Under an agreement reached April 26, 1993, the company will pay $13 million for $58 million purchase price and the balance in IVAX common stock. Assets to be...

  • Ivax gains recommendation in Europe for injectable paclitaxel anticancer drug.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p18 

    Reports on the European Medicines Evaluation Agency's recommendation of the extension of the marketing authorization for Ivax Corp.'s proprietary injectable Paclitaxel to include the treatment of metastatic breast cancer and metastatic ovarian cancer. Identification of Paclitaxel as the active...

  • Ivax receives expanded approval for cancer drug.  // PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p18 

    Focuses on the European Commission's expanded approval of Paxene, Ivax Corp.'s injectable form of the cancer drug paclitaxel, to cover the treatment of metastatic breast cancer and metastic ovarian cancer. Ivax's deal with Mayne Group Ltd. concerning marketing and distribution of Paxene in Europe.

  • JPC sold in merger with IVAX Corp. Chapelle, Tony // Black Enterprise;Sep93, Vol. 24 Issue 2, p15 

    Reports that Johnson Products Co. Inc. was acquired by the Miami-based IVAX Corp. in the summer of 1993. Other dramas which have impacted the company and the Johnson family; End of the company's 39 years of black ownership; Comment from IVAX chairman and CEO Dr. Philip Frost; More.

  • IVAX receives marketing approval for antihistamine.  // Drug Store News;4/7/97, Vol. 19 Issue 7, p61 

    Reports on the US Food and Drug Administration's approval of Ivax Corp.'s Abbreviated New Drug Application for terfenadine tablets USP. Company executive's comments on the approval; Zenit Goldline Pharmaceuticals' support of consumer education.

  • Ivax moves forward to bolster business unit sales performance. Popolillo, Melissa C. // Drug Store News;6/22/98, Vol. 20 Issue 9, pCP8 

    Discloses the efforts of drug firm Ivax Corp. to improve the operations of its business units. Hiring of Schroders to explore feasibility of initial public offering; Establishment of subsidiary firm; Possible change of name of parent firm to IVX BioSciences.

  • Ivax considers divesting specialties. Plishner, Emily S. // Chemical Week;12/22/1993, Vol. 153 Issue 24, p12 

    Reports on Ivax Corp.'s consideration of divesting its specialty chemicals business. Desire to maintain a balance between proprietary and generic drug products; 1992 revenues; Ivax as leading supplier of chemicals for use on denim fabrics; Specialty chemical earnings before depreciation and...

  • Ivax Corp. Rankin, Ken // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP16 

    Profiles Miami, Florida-based generic drug company Ivax Corp. Contact information; Financial performance; Business profile.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics